Table 2.

Analysis of factors predictive of event free survival (EFS) including the type of TKI modality.

	N	Events	Log-rank	HR	95% CI HR	P-value	5-year EFS
*Univariate
TKI Type
Imatinib 400#	68	21	0.009				72
Imatinib 800	200	37		0.55	(0.32–0.94)	0.029	84
Dasatinib	105	7		0.27	(0.11–0.64)	0.003	93
Nilotinib	108	11		0.44	(0.21–0.93)	0.031	84
Sokal score
Low	333	45	0.19				86
Intermediate	118	23		1.29	(0.78–2.13)	0.324	82
High	30	8		1.91	(0.90–4.06)	0.092	76
Age, years
≤55	322	50	0.91				84
>55	159	26		1.03	(0.64–1.65)	0.913	84
Splenomegaly (≥10cm)
No	445	64	0.003				86
Yes	36	12		2.44	(1.32–4.53)	0.005	70
Multivariate
TKI Type
Imatinib 400#	68	21					72
Imatinib 800	200	37		0.51	(0.29–0.88)	0.016	84
Dasatinib	105	7		0.28	(0.12–0.66)	0.004	92
Nilotinib	108	11		0.42	(0.20–0.89)	0.024	84
Splenomegaly (≥10cm)
No	445	64					86
Yes	36	12		2.1	(1.03–4.48)	0.043	70

^*White blood cell (WBC) count, Hemoglobin, platelet count, peripheral blood blasts, serum lactate dehydrogenase (LDH) are not significant (p=NS; data not shown),

^#Imatinib 400 is the reference for comparison with other 3 TKI modalities